For the quarter ending 2026-03-31, JAGX has $37,434K in assets. $53,186K in debts. $7,278K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash | 7,278 | 968 | 3,527 | 2,207 |
| Restricted cash | 2,786 | 6,864 | - | - |
| Accounts receivable, net | 68 | 1,521 | 1,437 | 1,173 |
| Other receivable | 212 | 177 | 67 | 143 |
| Inventory, net | 7,819 | 8,599 | 10,628 | 10,719 |
| Prepaid expenses and other current assets | 2,047 | 2,216 | 13,743 | 13,661 |
| Total current assets | 20,210 | 20,345 | 29,402 | 27,903 |
| Total property and equipment at cost | 987 | 1,021 | 1,033 | - |
| Accumulated depreciation | 564 | 558 | 550 | - |
| Property and equipment, net | 423 | 463 | 483 | 441 |
| Operating lease - right-of-use asset | 1,079 | 1,000 | 1,062 | 1,138 |
| Intangible assets, net | 15,553 | 16,021 | 17,285 | 17,545 |
| Other assets | 169 | 494 | 1,240 | 1,241 |
| Total assets | 37,434 | 38,323 | 49,472 | 48,268 |
| Accounts payable | 4,957 | 8,686 | 8,443 | 6,617 |
| Deferred revenue | 170 | 170 | 170 | 170 |
| Notes payable, net of discount (includes note designated at fair value option amounting to 18.9 million as of march 31, 2026, and 26.2 million as of december 31, 2025, respectively) | 22,077 | 27,440 | 23,108 | 18,572 |
| Series o convertible preferred stock 0.0001 par value 1,557,000 and 0 shares authorized at march 31, 2026 and december 31, 2025, respectively 1,241,928 and 0 shares issued and outstanding at march 31, 2026 and december 31, 2025 | 9,470 | - | - | - |
| Operating lease liability, current | 261 | 192 | 226 | 256 |
| Accrued liabilities | 3,751 | 4,166 | 4,175 | 3,603 |
| Total current liabilities | 40,686 | 40,654 | 36,122 | 29,218 |
| Deferred revenue, net of current portion | 340 | 382 | 425 | 468 |
| Derivative liability | 187 | - | - | - |
| Operating lease liability, net of current portion | 898 | 892 | 918 | 960 |
| Notes payable, net of discount, net of current portion (includes notes designated at fair value option amounting to 7.6 million as of march 31, 2026, and 5.7 million as of december 31, 2025, respectively) | 11,075 | 15,083 | 7,648 | 10,742 |
| Total liabilities | 53,186 | 57,011 | 45,113 | 41,388 |
| Preferred stock value-Series LPerpetual Preferred Stock | 0 | 2,485 | 2,485 | 2,485 |
| Preferred stock value-Series GConvertible Preferred Stock | - | - | 0 | 0 |
| Preferred stock value-Series IConvertible Preferred Stock | - | - | 0 | 0 |
| Preferred stock value-Series MPerpetual Preferred Stock | 0 | - | 0 | 0 |
| Preferred stock value-Series NPerpetual Preferred Stock | 0 | - | 0 | - |
| Common stock value-Common Stock Voting | 1 | 1 | 0 | 0 |
| Common stock value-Nonvoting Common Stock | 0 | 0 | 0 | 0 |
| Additional paid-in capital | 378,130 | 380,974 | 380,836 | 373,575 |
| Noncontrolling interest | -1,574 | -1,399 | -1,268 | -1,108 |
| Accumulated deficit | -391,067 | -399,916 | -376,855 | -367,353 |
| Accumulated other comprehensive loss | -1,242 | -833 | -839 | -719 |
| Total stockholders' deficit | -15,752 | -18,688 | 4,359 | 6,880 |
| Total liabilities and stockholders' deficit | 37,434 | 38,323 | 49,472 | 48,268 |
Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc. (JAGX)